Amanda M. Uber
No Rating Available
(Learn About Our Rating System)

Amanda M. Uber, DO

Languages spoken: English

Clinical Locations

Primary Location

Eccles Primary Children's Outpatient Services

81 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-213-3599
Get Directions

Dr. Uber received her medical degree from Arizona College of Osteopathic Medicine, Midwestern University. She completed her Pediatric residency at Stanford University/Lucile Packard Children’s Hospital-Stanford Children’s Health. She remained at Stanford and serving as Chief Resident for the Pediatric Residency Program with roles as both an inpatient hospitalist and a general outpatient pediatrician. She then completed her Pediatric Nephrology fellowship at Stanford University/Lucile Packard Children’s Hospital-Stanford Children’s Health before joining faculty at the University of Nebraska Medical Center and Children’s Hospital in Nebraska in 2021.

She is currently an Assistant Professor of Pediatrics at the University of Utah, in the Division of Pediatric Nephrology and Hypertension at Primary Children’s Medical Center. Dr Uber’s clinical interests include acute kidney injury, chronic kidney disease, dialysis and nutrition. She enjoys caring for complex patients with end-stage kidney disease on dialysis and those undergoing kidney transplantation. Dr Uber’s research interests include quality improvement, cardiac patients with kidney disease and nephrotoxin induced kidney injury.

Specialties

Board Certification

American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Nephrology)

Dr. Uber received her medical degree from Arizona College of Osteopathic Medicine, Midwestern University. She completed her Pediatric residency at Stanford University/Lucile Packard Children’s Hospital-Stanford Children’s Health. She remained at Stanford and serving as Chief Resident for the Pediatric Residency Program with roles as both an inpatient hospitalist and a general outpatient pediatrician. She then completed her Pediatric Nephrology fellowship at Stanford University/Lucile Packard Children’s Hospital-Stanford Children’s Health before joining faculty at the University of Nebraska Medical Center and Children’s Hospital in Nebraska in 2021.

She is currently an Assistant Professor of Pediatrics at the University of Utah, in the Division of Pediatric Nephrology and Hypertension at Primary Children’s Medical Center. Dr Uber’s clinical interests include acute kidney injury, chronic kidney disease, dialysis and nutrition. She enjoys caring for complex patients with end-stage kidney disease on dialysis and those undergoing kidney transplantation. Dr Uber’s research interests include quality improvement, cardiac patients with kidney disease and nephrotoxin induced kidney injury.

Board Certification and Academic Information

Academic Departments Pediatrics -Assistant Professor (Clinical)
Academic Divisions Nephrology & Hypertension
Board Certification
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Nephrology)

Education history

Undergraduate Major: Molecular Biology; Minors: Chemistry & Religious Studies - University of Denver B.S.
Professional Medical Osteopathic Medicine - Midwestern University Arizona College of Osteopathic Medicine D.O.
Residency Categorical Pediatrics - Stanford University School of Medicine Resident
Chief Resident Pediatrics - Stanford University School of Medicine Chief Resident
Fellowship Pediatric Nephrology - Stanford University School of Medicine Fellow
Fellowship Pediatric Nephrology - Stanford University School of Medicine Chief Fellow

Selected Publications

Journal Article

  1. Selewski DT, Gist KM, Deep A, Elbahlawan L, Fuhrman DY, Gelbart B, Gorga SM, Mah KE, Ollberding NJ, Reynaud S, Seo J, Soranno DE, Stanski NL, Starr MC, Uber AM, Askenazi DJ, Sutherland SM, Menon S, Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) Collaborativ (2026). Fluid accumulation and outcomes in children receiving continuous kidney replacement therapy: an appraisal of the WE-ROCK registry. Pediatric nephrology (Berlin, Germany),
  2. Goswami S, Gist KM, Bjornstad P, Ciccia E, Deep A, Gelbart B, Menon S, Marinari E, Ollberding NJ, Qutob D, Seo J, Soranno DE, Van Wyk B, Starr MC, Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) Collaborativ (2025). Hyperglycemia and kidney outcomes in critically ill children and young adults on continuous kidney replacement therapy. Pediatric nephrology (Berlin, Germany), 40(9), 2957-2966.
  3. Dolan KJ, Gist KM, Basalely A, Bottari G, Chakraborty A, Damian M, Fuhrman D, Hasson DC, Joseph C, Kwiatkowski D, Martin S, Nhan J, Ollberding N, Selewski DT, Soranno D, Starr MC, Strong A, Thadani S, Zang H, Arikan AA, WE-ROCK Collaborativ (2025). Functional outcomes in pediatric patients on renal replacement therapy in a worldwide registry. Nephrology, dialysis, transplantation,
  4. Menon S, Starr MC, Zang H, Collins M, Damian MA, Fuhrman D, Krallman K, Soranno DE, Webb TN, Slagle C, Joseph C, Martin SD, Mohamed T, Beebe ME, Ricci Z, Ollberding N, Selewski D, Gist KM, WE-ROCK investigator (2025). Characteristics and outcomes of children¿¿¿10 kg receiving continuous kidney replacement therapy: a WE-ROCK study. Pediatric nephrology (Berlin, Germany), 40(1), 253-264.
  5. Uber AM, Han J, Grimm P, Montez-Rath ME, Chaudhuri (2024). Defining systolic blood pressure normative values in hospitalized pediatric patients: a single center experience. Pediatric research, 95(7), 1860-1867.
  6. Gist KM, Menon S, Anton-Martin P, Bigelow AM, Cortina G, Deep A, De la Mata-Navazo S, Gelbart B, Gorga S, Guzzo I, Mah KE, Ollberding NJ, Shin HS, Thadani S, Uber A, Zang H, Zappitelli M, Selewski DT, WE-ROCK Investigator (2024). Time to Continuous Renal Replacement Therapy Initiation and 90-Day Major Adverse Kidney Events in Children and Young Adults. JAMA network open, 7(1), e2349871.
  7. Thadani S, Wu TC, Wu DTY, Kakajiwala A, Soranno DE, Cortina G, Srivastava R, Gist KM, Menon S, Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Diseases (WE-ROCK) Collaborator (2024). Machine Learning-Based Prediction Model for ICU Mortality After Continuous Renal Replacement Therapy Initiation in Children. Critical care explorations, 6(12), e1188.
  8. Starr MC, Gist KM, Zang H, Ollberding NJ, Balani S, Cappoli A, Ciccia E, Joseph C, Kakajiwala A, Kessel A, Muff-Luett M, Santiago Lozano MJ, Pinto M, Reynaud S, Solomon S, Slagle C, Srivastava R, Shih WV, Webb T, Menon S, Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) Collaborativ (2024). Continuous Kidney Replacement Therapy and Survival in Children and Young Adults: Findings From the Multinational WE-ROCK Collaborative. American journal of kidney diseases, 84(4), 406-415.e1.
  9. Fuhrman DY, Stenson EK, Alhamoud I, Alobaidi R, Bottari G, Fernandez S, Guzzi F, Haga T, Kaddourah A, Marinari E, Mohamed TH, Morgan CJ, Mottes T, Neumayr TM, Ollberding NJ, Raggi V, Ricci Z, See E, Stanski NL, Zang H, Zangla E, Gist KM, WE-ROCK Investigator (2024). Major Adverse Kidney Events in Pediatric Continuous Kidney Replacement Therapy. JAMA network open, 7(2), e240243.
  10. Stenson EK, Alhamoud I, Alobaidi R, Bottari G, Fernandez S, Fuhrman DY, Guzzi F, Haga T, Kaddourah A, Marinari E, Mohamed T, Morgan C, Mottes T, Neumayr T, Ollberding NJ, Raggi V, Ricci Z, See E, Stanski NL, Zang H, Zangla E, Gist KM, WE-ROCK Investigator (2024). Factors associated with successful liberation from continuous renal replacement therapy in children and young adults: analysis of the worldwide exploration of renal replacement outcomes collaborative in Kidney Disease Registry. Intensive care medicine, 50(6), 861-872.
  11. Stanski NL, Gist KM, Hasson D, Stenson EK, Seo J, Ollberding NJ, Muff-Luett M, Cortina G, Alobaidi R, See E, Kaddourah A, Fuhrman DY, Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) Investigator (2024). Characteristics and Outcomes of Children and Young Adults With Sepsis Requiring Continuous Renal Replacement Therapy: A Comparative Analysis From the Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK). Critical care medicine, 52(11), 1686-1699.
  12. Sedler J, Sutherland SM, Uber AM, Jahadi O, Ryan KR, Yarlagadda VV, Kwiatkowski D (2023). Clinical Predictive Tool for Pediatric Cardiac Patients on Extracorporeal Membrane Oxygenation Therapy and Ultrafiltration. ASAIO journal (American Society for Artificial Internal Organs, 69(7), 695-701.
  13. Miller P, Xiao AY, Kung VL, Sibley RK, Higgins JP, Kambham N, Charu V, Lenihan C, Uber A, Talley EM, Arora N, Walavalkar V, Laszik ZG, Nast CC, Troxell ML (2021). Progression of proliferative glomerulonephritis with monoclonal IgG deposits in pediatric patients. Pediatr Nephrol, 36(4), 927-937.
  14. Uber AM, Montez-Rath ME, Kwiatkowski DM, Krawczeski CD, Sutherland SM (2018). Nephrotoxin exposure and acute kidney injury in critically ill children undergoing congenital cardiac surgery. Pediatr Nephrol, 33(11), 2193-2199.
  15. Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R (2014). CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica, 99(4), 688-96.

Review

  1. Uber AM, Sutherland SM (2020). Nephrotoxins and nephrotoxic acute kidney injury. [Review]. Pediatr Nephrol, 35, (10), 1825-1833.
  2. Uber AM, Sutherland SM (2020). Acute kidney injury in hospitalized children: consequences and outcomes. [Review]. Pediatr Nephrol, 35, (2), 213-220.